MedTrace Logo

Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment

NCT03024684 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2024-11-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether statin could prevent recurrence of hepatocellular carcinoma after curative treatment

Conditions

Interventions

DRUG

Atorvastatin

Atorvastatin 10mg daily

DRUG

Placebo Oral Tablet

Placebo one tablet daily

Sponsors & Collaborators

  • E-DA Hospital

    collaborator OTHER

  • National Taiwan University Hospital

    collaborator OTHER

  • Taichung Veterans General Hospital

    collaborator OTHER

  • Mackay Memorial Hospital

    collaborator OTHER

  • Tainan Municipal Hospital

    collaborator OTHER

  • National Cheng-Kung University Hospital

    collaborator OTHER

  • Chi Mei Medical Hospital

    collaborator OTHER

  • Chiayi Christian Hospital

    lead OTHER

Principal Investigators

  • Po Yueh Chen, Doctor · Ditmanson Medical Foundation Chia-Yi Christian Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-03
Primary Completion
2025-01-31
Completion
2027-01-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03024684 on ClinicalTrials.gov